Business of Cannabis has the details
Coming just months after the first two individual applications were given positive risk assessments in May, this represents another major step forward for the UK CBD industry’s arduous journey towards full regulation.
EIHA’s RP427 application represents over 160 companies from across the UK, Europe and the US, and includes over 1000 products.
Given the complexities of attempting to approve hundreds of products at once, a strategy that was initially not allowed by the regulation, EIHA aimed to standardise the entire procedure, imposing strict guidelines on the starting material and extraction methods.
EIHA’s Managing Director, Lorenza Romanese, told Business of Cannabis: “It’s easier to pass one product, but it is not the same to standardise 160 companies on the market that do not speak the same language. So it required a lot of effort to sit down with partners and standardise their products.
“We made a huge effort to standardise the processes among the members of the consortium to ensure they were abiding by the stringent rules that make them compliant with what we have tested.”
EIHA Board Member and UK Representative, Tony Reeves said “This is indeed excellent news for our sector and a milestone moment not just for our EIHA members but for the market in general as it represents a real potential to boost consumer trust in the category, enhance retailer confidence and provide a catalyst for investment in the industry.”
What is included?
In October last year, the FSA published a shock update to its consumer guidance on the recommended daily dosage of CBD.
According to new ‘scientific evidence’, understood to have been gained from toxicological studies submitted by the industry itself, the FSA dropped its recommended daily intake (ADI) from 70mg a day to just 10mg a day.
Read their full report
